Paroxetine in Patients With Irritable Bowel Syndrome: A Pilot Open-Label Study.
BACKGROUND: Irritable bowel syndrome (IBS) is a common disorder and is the largest diagnostic cohort seen by gastroenterologists. There is a bidirectional comorbidity of IBS and psychiatric illness. Ours is the first study to examine the effect of any selective serotonin reuptake inhibitor in subjects with IBS. METHOD: Twenty subjects with Rome I criteria-diagnosed IBS were treated with 20 to 40 mg of paroxetine for 12 weeks. We utilized a computer-administered patient daily questionnaire taken by patients over the telephone using an interactive voice response system. RESULTS: Sixty-five percent of patients (13/20) reported a reduction in abdominal pain, and 55% (11/20) reported a reduction in pain frequency (total or mean number of days per week in which the patient had the symptom decreased by >/= 50%). Constipation and diarrhea were reduced in 69% and 57% of patients (9/13 and 8/14), respectively. Similarly, a clinically significant reduction in the symptoms of feeling of incomplete emptying (53% [9/17]) and bloating/abdominal distension (55% [11/20]) was apparent at study conclusion compared with baseline. On the Clinical Global Impressions scale at week 12, 47% (8/17) of the patients were much or very much improved. CONCLUSION: In our pilot open-label study, paroxetine was very effective in alleviating the abdominal pain and associated symptoms of IBS. These results warrant further examination in a placebo-controlled study.
Masand
Prakash S.
PS
Department of Psychiatry, Duke University Medical Center, Durham, N.C.; the Department of Psychiatry, Olean General Hospital West, Olean; Department of Psychiatry, SUNY Upstate Medical University, Syracuse; Syracuse Gastroenterological Associates, Syracuse, N.Y.; and Healthcare Technology Systems, Madison, Wis.
Gupta
Sanjay
S
Schwartz
Thomas L.
TL
Virk
Subhdeep
S
Lockwood
Kari
K
Hameed
Ahmad
A
King
Monica
M
Kaplan
David S.
DS